Aspects of drug development and clinical trials — Part 2

The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.

Buse JB , Ginsberg HN , Bakris GL et al. Primary prevention of cardiovascular disease in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26 and Diabetes Care 2007; 30:162-72.

Matfin G. Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk. Br J Diabetes Vasc Dis 2007;7:101-06.

Sonnenberg G. , Matfin G. , Reinhardt R. Drug treatments for obesity: where are we heading and how do we get there? Br J Diabetes Vasc Dis 2007;7:111-18.

Pratley R. , Matfin G. Pre-diabetes: clinical relevance and therapeutic approach. Br J Diabetes Vasc Dis 2007;7:120-6.

Alberti KG , Zimmet P. The metabolic syndrome: time to reflect. Curr Diabetes Rep 2006;6:259-61.

Day C. Metabolic syndrome or What you will: definitions and epidemiology. Diabetes Vasc Dis Res 2007;4:32-8.

Wald NJ , Law MR A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.

Reddy KS The prevention polypill - much promise, insufficient evidence. complications of diabetes. BMJ 2006;333:475-80. New Engl J Med 2007;356:212.

Marshall SM , Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 2006 33:475-80.